Industries > Pharma > Cancer Biologics Market Report 2023-2033
Back to Pharma Reports
Cancer Biologics Market Report 2023-2033

Cancer Biologics Market Report 2023-2033

Forecasts by Product (Monoclonal Antibodies (Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies), Vaccines (Preventive Vaccines, Therapeutic Vaccines), Cancer Growth Blockers (Tyrosine kinase Inhibitors (TKI), Proteasome Inhibitors (PI), mTOR Inhibitors), Blood Cell Growth Factors (Lenograstim, Filgrastim), Cytokine (Interferons, Interleukins)), by Application (Non-Small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukaemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other), by Route of Administration (Orals, Injectable) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

PUBLISHED: 22 June 2023
PAGES: 308
PRODUCT CODE: PHA1266
SUBMARKET: Therapeutic Drugs

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA1266 Categories: , Tags: , , ,

The Cancer Biologics Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing geriatric population will drive demand for cancer biologics therapy
Rising elderly population is one of the major factors driving the cancer biological therapy market growth. According to United Nation estimates, the global elderly population aged 60 years and above is set to double and reach over 2.1 billion by 2050 from over 962 million in 2017. Geriatric population is at a higher risk of acquiring various types of cancer such as lung cancer, colon cancer and breast cancer boosting the demand for cancer biological therapies. According to the National Center for Biotechnology Information (NCBI), cancer is one of the predominant causes of morbidity and mortality among the geriatric population base. Around 60% of all cancer cases and approximately 70% of cancer-related deaths occur in patients above 65 years of age. Thus, the increasing elderly population base suffering from cancer will propel the demand for cancer biological therapy, thereby fostering business growth.

Toxicity and Adverse Effects associated with Cancer Therapy
Anticancer drugs have severe side effects and its clinical usage for cancer therapy is limited by its toxicity. The adverse effects vary drug to drug for numerous reasons. They may be chronic or acute, mild, permanent, self-limited or potentially life threatening. Common side effects associated with the anti-cancer drugs include low blood counts that increase the possibility of developing infection or anaemia, mouth soreness, tiredness, nausea, loss of appetite, vomiting, constipation or diarrhoea, skin reactions, hair loss, pain or nerve changes. However, certain side effects can have long lasting or permanent effects. For example, certain chemotherapy drugs can result in infertility or the inability to father a child that may be permanent. Additionally, chemotherapy may lead to long-term damage to the lungs, heart, kidneys, and reproductive organs. Growing awareness among patients regarding side effects of cancer treatment may hamper patient preference towards the cancer therapy and can therefore impede the market growth during the coming years.

What Questions Should You Ask before Buying a Market Research Report?
• How is the Cancer Biologics Market evolving?
• What is driving and restraining the Cancer Biologics Market?
• How will each Cancer Biologics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each Cancer Biologics submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading Cancer Biologics Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the Cancer Biologics projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of Cancer Biologics projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the Cancer Biologics Market?
• Where is the Cancer Biologics Market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Cancer Biologics Market today, and over the next 10 years:
• Our 308-page report provides 117 tables and 187 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Cancer Biologics Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Cancer Biologics prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

By Product
• Monoclonal Antibodies
– Naked Monoclonal Antibodies
– Conjugated Monoclonal Antibodies
– Bispecific Monoclonal Antibodies
• Vaccines
– Preventive Vaccines
– Therapeutic Vaccines
• Cancer Growth Blockers
– Tyrosine kinase Inhibitors (TKI)
– Proteasome Inhibitors (PI)
– mTOR Inhibitors
• Blood Cell Growth Factors
– Lenograstim
– Filgrastim
• Cytokine
– Interferons
– Interleukins

By Application
• Non-Small Cell Lung Cancer
• Prostate Cancer
• Breast Cancer
• Acute Myeloid Leukaemia
• Lymphoma
• Multiple Myeloma
• Ovarian Cancer
• Colorectal Cancer
• Gastric Cancers
• Other Applications

By Route of Administration
• Oral
• Injectable

CTA

Regional and Country level Market estimates:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America Latin America

MEA
• GCC
• South Africa
• Rest of MEA

Cancer Biologics Market Report 2023-2033
Need industry data? Please contact us today.

The report also includes profiles and for some of the leading companies in the Cancer Biologics Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• AbbVie
• Amgen
• Astellas Pharma
• AstraZeneca PLC
• Bristol Myers Squibb
• Eisai Co., Ltd
• Eli Lilly and company
• F. Hoffmann-La Roche Ltd
• Merck & Co., Inc.
• Novartis AG
• Takeda Pharmaceutical Company

Overall world revenue for Cancer biologics market, 2023 to 2033 in terms of value the market will surpass US$ 115.9 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Cancer biologics market, 2023 to 2033 report help you?
In summary, our 300+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Cancer biologics market, 2023 to 2033 Market, with forecasts for product, application and route of administration, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for five regional and 16 key national markets – See forecasts for the Cancer biologics market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 11 of the major companies involved in the Cancer biologics market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Cancer biologics market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Cancer Biologics Market Report 2023-2033: Forecasts by Product (Monoclonal Antibodies (Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies), Vaccines (Preventive Vaccines, Therapeutic Vaccines), Cancer Growth Blockers (Tyrosine kinase Inhibitors (TKI), Proteasome Inhibitors (PI), mTOR Inhibitors), Blood Cell Growth Factors (Lenograstim, Filgrastim), Cytokine (Interferons, Interleukins)), by Application (Non-Small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukaemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other), by Route of Administration (Orals, Injectable) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Cancer Biologics Market Report 2023-2033

    Related reports

    Download sample pages

    Complete the form below to download your free sample pages for Cancer Biologics Market Report 2023-2033

      Connect with us

      Visiongain Pharma

      Visiongain Pharma

      Visiongain Pharma

      Latest Pharma news

      Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034

      The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.

      23 April 2024

      READ
      Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

      The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

      18 April 2024

      READ
      Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

      The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

      17 April 2024

      READ
      Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

      The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

      12 April 2024

      READ